Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

Vivek P Chavda; Aayushi B Patel; Lalitkumar K Vora; Vasso Apostolopoulos; Bruce D Uhal

doi:10.1080/14760584.2022.2110076

Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

Vivek P Chavda, Aayushi B Patel, Lalitkumar K Vora, Vasso Apostolopoulos, Bruce D Uhal

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

INTRODUCTION: A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.

AREA COVERED: Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.

EXPERT OPINION: With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.

Original language	English
Number of pages	9
Journal	Expert review of vaccines
Early online date	09 Aug 2022
DOIs	https://doi.org/10.1080/14760584.2022.2110076
Publication status	Early online date - 09 Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14760584.2022.2110076Licence: Unspecified

Cite this

@article{e1f6f1465c2f4618a344c90fc294765f,

title = "Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management",

abstract = "INTRODUCTION: A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.AREA COVERED: Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.EXPERT OPINION: With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.",

author = "Chavda, {Vivek P} and Patel, {Aayushi B} and Vora, {Lalitkumar K} and Vasso Apostolopoulos and Uhal, {Bruce D}",

year = "2022",

month = aug,

day = "9",

doi = "10.1080/14760584.2022.2110076",

language = "English",

journal = "Expert review of vaccines",

issn = "1744-8395",

publisher = "Taylor and Francis",

}

TY - JOUR

T1 - Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

AU - Chavda, Vivek P

AU - Patel, Aayushi B

AU - Vora, Lalitkumar K

AU - Apostolopoulos, Vasso

AU - Uhal, Bruce D

PY - 2022/8/9

Y1 - 2022/8/9

N2 - INTRODUCTION: A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.AREA COVERED: Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.EXPERT OPINION: With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.

AB - INTRODUCTION: A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.AREA COVERED: Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.EXPERT OPINION: With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.

U2 - 10.1080/14760584.2022.2110076

DO - 10.1080/14760584.2022.2110076

M3 - Article

C2 - 35929957

SN - 1744-8395

JO - Expert review of vaccines

JF - Expert review of vaccines

ER -

Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this